论文部分内容阅读
多中心观察和比较普找他汀(pravastatin)与吉非贝齐(gemfibrozil)对原发性高胆固醇血症(Ha或Hb型)的治疗作用和安全性.普伐他汀组90例,给药10～40mg,每晚1次,吉非贝齐组37例,给药600mg,每日2次,疗程12周.治疗结束时普伐他汀组和吉非贝齐组服药前后比较,血清总胆固醇(TC)平均降低21%和12%,低密度脂蛋白一胆固醇(LDI-C)平均降低29%和13%,甘油三酯(TG)平均降低20/和43%,对高密度脂蛋白一胆固醇(HDL-C)的作用,普伐他订组和吉非贝齐组平均升高4%和15%.结论:普伐他汀降低血清TC和LDL-C的作用比吉非贝齐更有效,降低血清TG和升高HDL-C的作用吉非贝齐比普伐他汀更有效.两组副反应情况类似,但普伐他汀组程度较轻.
The efficacy and safety of pravastatin and gemfibrozil on primary hypercholesterolemia (Ha or Hb type) were observed and compared by multicentre.Of 90 cases in pravastatin group, 10 ~ 40mg, once a night, 37 cases of gemfibrozil group, 600mg, 2 times a day, the course of treatment for 12 weeks.When the end of treatment, pravastatin group and gemfibrozil group before and after treatment, serum total cholesterol TC) decreased by 21% and 12% on average, LDL-C decreased by 29% and 13% on average, and triglycerides decreased by 20% and 43% on average, respectively. High-density lipoprotein-cholesterol (HDL-C), with an average increase of 4% and 15% in pravastatin and gemfibrozil groups.Conclusion: Pravastatin can lower the serum TC and LDL-C more effectively than gemfibrozil, Lowering serum TG and increasing HDL-C Gemfibrozil is more effective than pravastatin, with similar side effects in both groups but less in the pravastatin group.